Results 211 to 220 of about 15,393,463 (311)
Performance comparison of large language models in boron neutron capture therapy knowledge assessment. [PDF]
Shen S +7 more
europepmc +1 more source
Gut microbiota alterations in patients with non‐small‐cell lung cancer undergoing chemoradiotherapy
We investigated the impact of concurrent chemoradiotherapy (CRT) on the gut microbiota in patients with locally advanced non‐small‐cell lung cancer. Overall gut microbiota composition remained largely stable throughout CRT while antibiotic exposure may influence microbial diversity.
Hanne Marte Nymoen +19 more
wiley +1 more source
Performance Comparison of U-Net and Its Variants for Carotid Intima-Media Segmentation in Ultrasound Images. [PDF]
Jeong S, Park M, Jeong S, Park DC.
europepmc +1 more source
Extracellular vesicle (EV) lipidomic profiling of plasma and ascites from patients with high‐grade serous ovarian cancer and of ovarian cancer cell lines reveals enrichment of triglycerides (TGs), diacylglycerols (DGs), phosphatidylcholine (PCs), sphingomyelins (SMs), reflecting tumor metabolic reprogramming.
Shikha Rani +9 more
wiley +1 more source
AI-Assisted Prostate Cancer Diagnosis Using Biparametric MRI and PI-RADS v2.1: Performance Comparison Between Novice-Level and Experienced Readers. [PDF]
Li K +8 more
europepmc +1 more source
Performance Comparison of Cloud Databases
Martin Zboril, Vlasta Svatá
openaire +2 more sources
Loss of eIF5A rewires thapsigargin‐mediated endoplasmic reticulum stress responses in multiple myeloma cells by selective translation of mRNA transcripts, consequently dampening thapsigargin‐induced unfolded protein response (UPR) activation and shifting the balance from induction of apoptosis toward cell survival and proliferation.
Demi Both +7 more
wiley +1 more source
Performance comparison of MPPT controllers in a grid-connected PV system: LCOE and payback period approaches. [PDF]
Babu PC +5 more
europepmc +1 more source
High‐risk bladder cancer is typically treated with Bacillus Calmette‐Guérin (BCG), but 30–40% of patients relapse. No FDA‐ or CE‐approved biomarkers currently predict or prognosticate BCG failure. We systematically reviewed the literature and identified 72 eligible studies, revealing several promising biomarkers associated with BCG treatment response ...
Rui Ribeiro‐Pereira +7 more
wiley +1 more source

